Drostanolone Propionate

Package leaflet (information for patients)

Tradename
Drostanolone Propionate

Dosage form
Solution for injection 100mg / ml.

Description
Transparent liquid of light yellow color with a weak odor.

Structure
1 ml of solution contains:
Active ingredients: Drostanolone Propionate 100mg.
Auxiliary components: ethyl oleate.

Pharmacotherapeutic group
Androgens, antiandrogens. Antineoplastic hormonal agents and hormone antagonists.

Pharmacological properties
Pharmacological action - antitumor, androgenic.
It has an androgenic (less pronounced compared to testosterone propionate) and anabolic (more pronounced than testosterone propionate) effects. It has an antitumor effect in cancer of the thymus gland, incl. in the presence of metastases, as well as in patients whose ovarian function is suppressed by radiation, androgenic drugs, or who have undergone oophorectomy. More effective for bilateral oophorectomy.

Indications for use
Breast cancer, incl. with metastases, in women with a preserved menstrual cycle or in menopause up to 5 years.

Method of administration and dosage
The dosage regimen is individual, depending on the indications, the stage of the disease, the scheme of anticancer therapy and the dosage form.

Side effects
Hypersensitivity, acute diseases of the liver, kidneys, cardiovascular system (myocardial infarction, severe arterial hypertension, hypertensive crisis), hypercalcemia, end-stage breast cancer.

Contraindication
Acute liver and kidney disease, hypercalcemia, cardiovascular disease, end-stage disease.
Contraindicated in acute liver diseases.
Contraindicated in acute kidney disease.

Overdose
Symptoms: hepatotoxicity and intoxication. During intoxication, sweating, nausea, and vomiting may occur. These symptoms can be eliminated by reducing the dose.
Treatment: in case of signs of poisoning, induce vomiting or gastric lavage, prescribe activated charcoal and a laxative, and consult a doctor.
Intoxication and hepatotoxicity are more likely in elderly patients and especially in young children (therapeutic overdose or accidental intoxication can be very dangerous for them).

Precautions
Used in women with a preserved menstrual cycle or menopause up to 5 years. More effective after bilateral oophorectomy or suppression of ovarian function by radiation.
Interaction with other medicinal products
If you take other drugs or supplements at the same time as this drug, Drostanolone's effectiveness may change. Tell your healthcare provider about all drugs, vitamins, and supplements you use. Your doctor will be able to make the right dosing plan to avoid negative interactions

Special instructions
Peliosis of hepatitis can occur in patients receiving anabolic steroids. These cysts may be present with minimal liver dysfunction, but they are associated with a liver defect. Symptoms are often not recognized until a life-threatening liver problem or intra-abdominal bleeding develops. Discontinuation of anabolic steroid treatment usually leads to complete disappearance of the lesions. Tumors in liver cells have also been reported. Many of these tumors are benign and estrogen dependent, but fatal malignant tumors have also been reported; discontinuation of the drug may lead to regression or cessation of tumor development. Even though androgen-related or anabolic steroid-related liver tumors, they are much more vascular than other liver tumors and may not appear until life-threatening intra-abdominal hemorrhage develops. Changes in blood lipids associated with an increased risk of arteriosclerosis in patients taking androgens and anabolic steroids. These changes include a decrease in high density lipoprotein changes and sometimes an increase in low density lipoprotein. The changes can be very noticeable and should seriously affect the risk of changes in blood lipids associated with an increased risk of arteriosclerosis in patients taking androgens and anabolic steroids

Pregnancy and elbowing
This drug should not be used during pregnancy and lactation.
During pregnancy, the drug can cause virilization in female fetuses.
During breastfeeding, it is not known how anabolic steroids are excreted in breast milk. In accordance with the adverse reactions that may occur in infants, it is necessary to decide whether to stop breastfeeding or stop taking the drug.

Influence on the ability to drive vehicles and work with mechanisms
Does not affect.

Storage conditions
Store in a dry, dark place at a temperature not exceeding 25 ° C, out of the reach of children.

Shelf life
3 years. Do not use after the expiration date printed on the package.

Vacation conditions
On prescription.

Packaging
The solution is in 1 ml glass ampoules. Each ampoule is fixed in a plastic clip for 5 ampoules. 5 ampoules are packed in a cardboard box in a fixer together with an enclosed leaflet.